A review of the therapeutic management of ulcerative colitis

Aslam, Nasar; Lo, Sheng Wei; Sikafi, Rafid; Barnes, Tom; Segal, Jonathan; Smith, Philip J.; Limdi, Jimmy K.

doi:10.1177/17562848221138160

Cited by 19 publications

(15 citation statements)

References 135 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These therapies work by modulating or suppressing the immune system to reduce in ammation in the gut and alleviate symptoms associated with IBD. However, it is important to note that these treatments may have side effects and may not work for everyone, highlighting the need for continued research into alternative therapeutic options (43).…”

Section: Discussionmentioning

confidence: 99%

Anti-inflammatory peptides as promising therapeutics agent against inflammatory bowel diseases: A systematic review

Ghazvini,

Amirfakhrian,

Taghiabadi

2023

Preprint

View full text Add to dashboard Cite

Background Inflammatory bowel disease (IBD) is still an idiopathic condition; however, is probably associated to the dysregulation of gut mucosal immunity, intestinal microbiota dysbiosis, and environmental risk factors. Therefore, need call for novel therapeutic strategies. We aim to systematically review the latest current evidence on anti-inflammatory peptides (AIPs) as a new treatment approach in IBD, particularly by focus on Ulcerative Colitis and Cron’s diseases. Methodology: This systematic study was carried out in February 2023 following PRISMA 2020 guideline. Published studies that investigate the use of anti-inflammatory peptides for IBD treatment in were retrieved through searches of the literature in the Medline, Web of Science, and Cochrane databases. Results Seventeen studies satisfied the predesigned criteria and were involved, in which 12 of them used animal models of IBD, 4 were clinical trials, and one study was case-control. Results showed that H-SN1, a peptide derived from the snake’s venom and glucagon-like peptide-2 dimer (GLP-2②), significantly inhibits TNF cytotoxicity. Moreover, oral administration of AVX-470 (bovine-derived, anti-TNF antibody) reduced TNF, MPO, and apoptosis levels in enterocytes. Maintaining gut hemostasis and reversing gut dysbiosis could be effective in IBD treatment which Ac2-26 (a peptide that mimics annexin A1) and a combination of the αs2-casein peptide with synbiotics were helpful in this condition. AMP-18 (gastrokine-1) and MBCP (peptide derived from buffalo milk) can aid in preserving the intestinal barrier’s integrity by stabilizing tight junctions (TJs). This could potentially prevent IBD from occurring. Conclusion AIPs help reduce inflammation, regulate gut microbiota, and stabilize the intestinal barrier. However, their effectiveness can be limited due to destruction by proteases or harm to host cells. Further research should focus on improving their pharmacokinetic characteristics for better therapeutic potential.

show abstract

Section: Discussionmentioning

confidence: 99%

Anti-inflammatory peptides as promising therapeutics agent against inflammatory bowel diseases: A systematic review

Ghazvini,

Amirfakhrian,

Taghiabadi

2023

Preprint

View full text Add to dashboard Cite

show abstract

“…The management of inflammatory bowel disease (IBD) has advanced significantly in recent years, with the increasing availability of biologic agents, but compared to other immune-mediated pathologies, they are still insufficient [22]. Therefore, TDM is one of the most important keys to optimizing individual therapy.…”

Section: Discussionmentioning

confidence: 99%

Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies’ Determination against ELISA

Toja-Camba,

García-Quintanilla,

Rodríguez-Martinez

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

The introduction of point-of-care (POC) assays into clinical practice in patients with inflammatory disease enables on-demand therapeutic decision making. The aim of this study was to compare the POC test Quantum blue (Bühlmann Laboratories) for infliximab (IFX), adalimumab (ADL), and its anti-drug antibodies with the traditional ELISA assay (Promonitor). A total of 200 serum samples were analyzed. Samples were classified into the following three different groups; sub-therapeutic range (IFX < 3 μg/mL and ADL < 5 μg/mL); therapeutic range (IFX: 3–7 μg/mL and ADL: 5–12 μg/mL) and supra-therapeutic range (IFX levels > 7 μg/mL and ADL levels > 12 μg/mL). Significant higher values were measured using the POC test (p < 0.001) for IFX results but no differences in ADL trough levels were observed (p = 0.3101). Spearman’s correlation indicated a good correlation between the two assays (rs = 0.88 for ADL and rs = 0.93 for IFX), and McNemar’s test revealed significant differences (p = 0.016) when classifying IFX samples between therapeutic and supra-therapeutic ranges but no significant differences were found among the other ranges for either IFX or ADL. These results show that we should be cautious when using these rapid measurement methods, and new targets should probably be defined for IFX when using this new analytical method.

show abstract

“…Currently, the main pharmacological approaches for managing IBD include the use of azathioprine, glucocorticoids, 5-aminosalicylates, and cyclosporine. Unfortunately, long-term administration of these pharmaceutical agents can have significant adverse side effects, highlighting the importance of exploring alternative therapeutic approaches derived from natural resources and functional foods. , Notably, in vitro and in vivo models using isolated compounds have been employed to study the impact of specific polyphenols on gut inflammation. , However, this strategy has some inherent drawbacks, including the high cost of purchasing large quantities of purified compounds and the understanding that the food matrix and its interactions with other nutritional components can significantly influence the bioavailability and bioactivity of dietary polyphenols. , Therefore, the present research was designed to investigate whether Virofree, a supplement that consists of multiplant extracts, has the ability to modulate the composition of the microbiota and thereby alleviate the severity of colitis.…”

Section: Introductionmentioning

confidence: 99%

Virofree Associates with the Modulation of Gut Microbiomes and Alleviation of DSS-Induced IBD Symptoms in Mice

Lin,

Cheng,

Pan

2023

ACS Omega

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a chronic, nonspecific inflammation of the intestines that primarily comprises Crohn's disease and ulcerative colitis. The incidence and prevalence of IBD have been increasing globally, highlighting the significance of research and prophylactic interventions. Virofree, a mixture of various botanical extracts (including grapes, cherries, olive leaves, marigolds, green tea, and others), has shown significant potential in disease prevention. This study examined the effects of Virofree on intestinal inflammation and the gut microbiota in mice using a dextran sulfate sodium (DSS)-induced model. The mice showed no adverse reactions when administered Virofree. Virofree administration reduced the disease activity index as indicated by amelioration of DSS-induced symptoms in the mice, including weight loss, diarrhea, and rectal bleeding. Regarding the gut microbiota, Virofree intervention modulated the DSS-induced decrease in gut microbial diversity; the Virofree group showed no increase in the phyla Proteobacteria or Verrucomicrobia while displaying an increase in the genus Duncaniella, bacteria that may have protective properties. These findings suggest that Virofree may have a direct or indirect impact on the composition of the gut microbiota and that it can alleviate the imbalance of the microbiome and intestinal inflammation caused by DSS treatment.

show abstract

A review of the therapeutic management of ulcerative colitis

Cited by 19 publications

References 135 publications

Anti-inflammatory peptides as promising therapeutics agent against inflammatory bowel diseases: A systematic review

Anti-inflammatory peptides as promising therapeutics agent against inflammatory bowel diseases: A systematic review

Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies’ Determination against ELISA

Virofree Associates with the Modulation of Gut Microbiomes and Alleviation of DSS-Induced IBD Symptoms in Mice

Contact Info

Product

Resources

About